Quantamental Technologies LLC acquired a new position in shares of Cambrex Co. (NYSE:CBM) during the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 2,131 shares of the biotechnology company’s stock, valued at approximately $100,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Federated Investors Inc. PA acquired a new stake in shares of Cambrex during the first quarter worth approximately $15,991,000. Granite Investment Partners LLC raised its holdings in shares of Cambrex by 54.5% during the first quarter. Granite Investment Partners LLC now owns 445,764 shares of the biotechnology company’s stock worth $17,318,000 after acquiring an additional 157,298 shares in the last quarter. Lazard Asset Management LLC raised its holdings in shares of Cambrex by 16.8% during the first quarter. Lazard Asset Management LLC now owns 924,844 shares of the biotechnology company’s stock worth $35,930,000 after acquiring an additional 133,133 shares in the last quarter. Royce & Associates LP boosted its position in Cambrex by 195.7% during the first quarter. Royce & Associates LP now owns 178,900 shares of the biotechnology company’s stock valued at $6,950,000 after purchasing an additional 118,400 shares during the last quarter. Finally, American Capital Management Inc. boosted its position in Cambrex by 14.3% during the first quarter. American Capital Management Inc. now owns 764,238 shares of the biotechnology company’s stock valued at $29,691,000 after purchasing an additional 95,441 shares during the last quarter.
A number of equities research analysts have recently weighed in on CBM shares. ValuEngine raised Cambrex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 8th. Craig Hallum cut Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target for the company. in a research note on Monday, August 12th. William Blair downgraded Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price objective on the stock. in a report on Wednesday, August 7th. Finally, Zacks Investment Research downgraded Cambrex from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $52.00.
Cambrex stock traded down $0.08 during mid-day trading on Wednesday, hitting $59.90. 22,057 shares of the company’s stock were exchanged, compared to its average volume of 773,343. The company has a current ratio of 2.44, a quick ratio of 1.77 and a debt-to-equity ratio of 0.78. The stock has a market cap of $2.02 billion, a P/E ratio of 21.62, a P/E/G ratio of 4.68 and a beta of 2.24. Cambrex Co. has a 1-year low of $33.80 and a 1-year high of $69.43. The stock has a 50 day moving average of $54.75 and a two-hundred day moving average of $45.12.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Further Reading: What is quantitative easing?
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.